top of page


  • Item Description

• Epigenetic test for quantifying cigarette smoking using a small amount of DNA from whole blood or saliva.
• Detects changes in the DNA methylation at the aryl hydrocarbon receptor repressor (AHRR)
• Optimized for digital PCR technologies

The Smoke Signature™ assay was developed by Behavioral Diagnostics, LLC. It is the first smoking detection/quantification assay, based on differential methylation in the aryl hydrocarbon receptor repressor (AHRR) particularly at CpG residue cg05575921. This assay has been optimized for droplet digital PCR (ddPCR).

A New Epigenetic Test for Quantifying Cigarette Smoking
Smoking has a profound effect on risk for many diseases, such as diabetes and atherosclerosis and affects many biological processes including gene expression and cytokine levels. Quantifying those effects of smoking is often difficult given the unreliability of smoking data—particularly in samples from high-risk populations. The newly developed Smoke Signature™ assay, which measures the change of DNA methylation in the aryl hydrocarbon receptor repressor, completely overcomes that problem. Using this test and a small amount of DNA from whole blood, investigators can easily determine the cigarette consumption history of any individual—even in the absence of any other clinical information.

US Patent # 8,637,652 and 9,273,358 apply.

Manufactured in Iowa.


  • Specifications

Kit Contents

2X Pre-Amp Assay - 1 ml 20X Smoke Signature™ Assay (Blood) - 200 µl "C" Control Plasmid - 50 µl "T" Control Plasmid - 50 µl


  • Protocol

Smoke Signature™ Assay - Protocol


  • Technical Information


Smoke Signature™ Assay - Overview Flyer

Bulletin 1

    bottom of page